- Home
- XENE vs CZR Comparison
XENE vs CZR Comparison
Compare XENE & CZR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XENE | CZR |
|---|---|---|
| Founded | 1996 | 1937 |
| Country | Canada | United States |
| Employees | N/A | 15500 |
| Industry | Biotechnology: Pharmaceutical Preparations | Hotels/Resorts |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.2B | 6.0B |
| IPO Year | 2014 | 2015 |
Fundamental Metrics
Financial Performance| Metric | XENE | CZR |
|---|---|---|
| Price | $55.81 | $29.50 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 13 |
| Target Price | ★ $68.55 | $31.92 |
| AVG Volume (30 Days) | 1.5M | ★ 9.5M |
| Earning Date | 05-08-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $311,000.00 | ★ $1,473,504,000.00 |
| Revenue This Year | N/A | $3.56 |
| Revenue Next Year | $2,496.48 | $2.48 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 65.03 |
| 52 Week Low | $30.00 | $17.86 |
| 52 Week High | $62.91 | $31.58 |
Technical Indicators
Market Signals| Indicator | XENE | CZR |
|---|---|---|
| Relative Strength Index (RSI) | 60.01 | 65.01 |
| Support Level | $52.40 | $27.22 |
| Resistance Level | $56.66 | $29.58 |
| Average True Range (ATR) | 1.72 | 0.19 |
| MACD | 0.46 | -0.06 |
| Stochastic Oscillator | 86.26 | 83.67 |
Price Performance
Historical ComparisonAbout XENE Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.
About CZR Caesars Entertainment Inc.
Caesars Entertainment's stand-alone portfolio includes about 50 domestic gaming properties across the Las Vegas (48% of 2025 EBITDAR) and regional (49%) markets. Additionally, the company hosts managed properties and digital assets that produced marginal EBITDA in 2025. Caesars' US presence roughly doubled with the 2020 acquisition by Eldorado, which built its first casino in Reno, Nevada, in 1973. Caesars' brands include Caesars, Harrah's, Tropicana, Bally's, Isle, and Flamingo. Also, the company owns the US portion of William Hill (it sold the international operation in 2022), a digital sports betting platform. The portfolio is set to expand to more than 60 casinos with the proposed acquisition of Caesars by Fertitta Entertainment and its Golden Nugget resorts.